Related Experiment Video
Updated: Jun 27, 2026
Bone Marrow-derived Macrophage Production
Published on: November 22, 2013
[Effects of paclitaxel on the macrophages derived from bone marrow cells in vitro]
1Department of Animal Science and Technology, Beijing University of Agriculture, Beijing 102206, China. long.lil81@yahoo.com.cn
Aim:
To Study on the effects of paclitaxel on macrophages derived from the mouse bone marrow cells.
Methods:
The bone marrow cells flushed from BALB/c tibia, femur and hipbone were resuspended in RPMI1640 containing M-CSF and seeded in six-well plates. Then they were cultured in RPMI1640 containing M-CSF in the presence or absence of paclitaxel for seven days. The phenotypes and phagocytosis of the macrophages derived from mice bone marrow cells were measured by FCM and their antigen presentation was detected by DTH.
Results:
The expression of CD80 and CD14 in paclitaxal-treated macrophages was increased and their function of phagocytosis was significantly enhanced. More reduction appeared in DTH reaction of the macrophages treated with palitaxal compared with that in the macrophages derived from control group.
Conclusion:
Paclitaxel can significantly enhance the phagocytosis of the macrophages derived from bone marrow cells and decrease their immunogenicity, which indicates that paclitaxal may regulate the immunological function of the macrophages derived from bone marrow cells.
Insights
Paclitaxel enhances macrophage phagocytosis and reduces immunogenicity in mouse bone marrow cells. This suggests paclitaxel modulates macrophage immune function.
Area of Science:
- Immunology
- Cell Biology
Background:
- Macrophages are crucial immune cells involved in host defense and immune regulation.
- Bone marrow-derived macrophages (BMMs) are a common model for studying macrophage biology.
- Paclitaxel is a chemotherapy drug with known immunomodulatory effects.
Purpose of the Study:
- To investigate the effects of paclitaxel on the phenotype and function of mouse bone marrow-derived macrophages.
- To assess paclitaxel's impact on macrophage phagocytosis and antigen presentation.
Main Methods:
- Mouse bone marrow cells were cultured with M-CSF to differentiate into macrophages.
- Macrophages were treated with paclitaxel or vehicle control for seven days.
- Flow cytometry (FCM) was used to analyze macrophage phenotype (CD80, CD14) and phagocytosis.
- Delayed-type hypersensitivity (DTH) reaction was used to assess antigen presentation.
Main Results:
- Paclitaxel treatment increased the expression of CD80 and CD14 on macrophages.
- Macrophage phagocytic activity was significantly enhanced by paclitaxel.
- Paclitaxel-treated macrophages showed a reduced DTH reaction compared to controls.
Conclusions:
- Paclitaxel significantly enhances the phagocytic capacity of bone marrow-derived macrophages.
- Paclitaxel decreases the immunogenicity of macrophages, as indicated by reduced DTH reactions.
- Paclitaxel demonstrates a regulatory role in the immunological function of macrophages.
